ArticleClinical lymphoma, myeloma & leukemia2026
Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance.
Oren Pasvolsky et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.